A study of the clinical, treatment planning and dosimetric feasibility of dose painting in external beam radiotherapy of prostate cancer
- PMID: 33458328
- PMCID: PMC7807863
- DOI: 10.1016/j.phro.2020.07.005
A study of the clinical, treatment planning and dosimetric feasibility of dose painting in external beam radiotherapy of prostate cancer
Abstract
Background and purpose: Radiotherapy dose painting is a promising technique which enables dose escalation to areas of higher tumour cell density within the prostate which are associated with radioresistance, known as dominant intraprostatic lesions (DILs). The aim of this study was to determine factors affecting the feasibility of radiotherapy dose painting in patients with high and intermediate risk prostate cancer.
Materials & methods: Twenty patients were recruited into the study for imaging using a 3 T magnetic resonance imaging (MRI) scanner. Identified DILs were outlined and the scan registered with the planning computed tomography (CT) dataset. Intensity-modulated plans were produced and evaluated to determine the effect of the organ-at-risk constraints on the dose that could be delivered to the DILs. Measurements were made to verify that the distribution could be safely delivered.
Results: MRI scans were obtained for nineteen patients. Fourteen patients had one to two DILs with ten overlapping the urethra and/or rectum. The target boost of 86 Gy was achieved in seven plans but was limited to 80 Gy for five patients whose boost volume overlapped or abutted the urethra. Dosimetric measurements gave a satisfactory gamma pass rate at 3%/3 mm.
Conclusions: It was feasible to produce dose-painted plans for a boost of 86 Gy for approximately half the patients with DILs. The main limiting factor was the proximity of the urethra to the boost volumes. For a small proportion of patients, rigid registration between CT and MRI images was not adequate for planning purposes.
Keywords: Computer-assisted/methods; Feasibility studies; Focal boost; Intensity-modulated/methods; Magnetic resonance imaging; Multi-parametric MRI; Prostate radiotherapy; Radiotherapy; Radiotherapy dosage; Radiotherapy planning; Urethra.
© 2020 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
Similar articles
-
Effect of androgen deprivation therapy on intraprostatic tumour volume identified on 18F choline PET/CT for prostate dose painting radiotherapy.Br J Radiol. 2017 Mar;90(1071):20160818. doi: 10.1259/bjr.20160818. Epub 2016 Dec 20. Br J Radiol. 2017. PMID: 27993093 Free PMC article.
-
Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions.Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):406-15. doi: 10.1016/j.ijrobp.2014.01.042. Epub 2014 Mar 28. Int J Radiat Oncol Biol Phys. 2014. PMID: 24685447 Free PMC article.
-
Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy.Br J Radiol. 2019 May;92(1097):20190089. doi: 10.1259/bjr.20190089. Epub 2019 Apr 9. Br J Radiol. 2019. PMID: 30912959 Free PMC article.
-
Cone beam CT-based dose accumulation and analysis of delivered dose to the dominant intraprostatic lesion in primary radiotherapy of prostate cancer.Radiat Oncol. 2021 Oct 26;16(1):205. doi: 10.1186/s13014-021-01933-z. Radiat Oncol. 2021. PMID: 34702305 Free PMC article.
-
Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging.Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1196-207. doi: 10.1016/j.ijrobp.2004.02.055. Int J Radiat Oncol Biol Phys. 2004. PMID: 15234056
Cited by
-
Improving prostate brachytherapy outcomes through MRI-Assisted dominant lesion dose painting.BMC Urol. 2025 Mar 15;25(1):54. doi: 10.1186/s12894-025-01731-9. BMC Urol. 2025. PMID: 40089687 Free PMC article.
-
A statistical, voxelised model of prostate cancer for biologically optimised radiotherapy.Phys Imaging Radiat Oncol. 2022 Mar 6;21:136-145. doi: 10.1016/j.phro.2022.02.011. eCollection 2022 Jan. Phys Imaging Radiat Oncol. 2022. PMID: 35284663 Free PMC article.
-
Focal Boost in Prostate Cancer Radiotherapy: A Review of Planning Studies and Clinical Trials.Cancers (Basel). 2023 Oct 8;15(19):4888. doi: 10.3390/cancers15194888. Cancers (Basel). 2023. PMID: 37835581 Free PMC article. Review.
-
Optimizing the dose-averaged linear energy transfer for the dominant intraprostatic lesions in high-risk localized prostate cancer patients.Phys Imaging Radiat Oncol. 2025 Feb 7;33:100727. doi: 10.1016/j.phro.2025.100727. eCollection 2025 Jan. Phys Imaging Radiat Oncol. 2025. PMID: 40026913 Free PMC article.
References
-
- Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., van Putten W.L.J., Slot A., Dielwart M.F.H. Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 Gy. J Clin Oncol. 2006;24:1990–1996. doi: 10.1200/JCO.2005.05.2530. - DOI - PubMed
-
- Van Der Heide U.A., Korporaal J.G., Groenendaal G., Franken S., Van Vulpen M. Functional MRI for tumor delineation in prostate radiation therapy. Imaging Med. 2011;3:219–231. doi: 10.2217/iim.11.10. - DOI
LinkOut - more resources
Full Text Sources